Submitted by Anonymous (not verified) on 3 July 2026 - 11:40
Opinion/decision on a Paediatric investigation plan (PIP): Ocrevus, ocrelizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: EMA/PE/0000237224
Source: